Kai He, MD, PHD
Academic Title: Associate Professor in the College of Medicine
Research Program: Translational Therapeutics
About Me
More info forI am a board-certified medical oncologist and assistant professor of medicine in the Thoracic Oncology Program at The Ohio State University. I have expertise in the personalized care of patients with thoracic malignancies, including lung cancer, pleural mesothelioma and thymic carcinoma, based on their unique clinical, genetic and immunological characteristics. I completed my clinical and research fellowships in Medical Oncology at Johns Hopkins Hospital, where I was awarded a T32 training grant for studying epigenetics and cancer immunity in lung cancer, and finished my PhD training in Cell Biology at the University of Alabama at Birmingham. As a physician-scientist in the Translational Therapeutics Program at the OSUCCC – James, my research focuses on cancer epigenetics, genomics and immunology, and their associated novel biomarker and therapeutic development in lung cancer. My lab studies the determinants for the response and resistance to immunotherapy in lung cancer, from the genomic instability and tumor mutation-related neoantigen to the dynamic immune landscape evolution related to immunotherapy. I have co-authored over 30 publications in peer-reviewed journals, including Cancer Discovery, Journal of Thoracic Oncology, Clinical Lung Cancer and Journal of Hematology & Oncology. I currently serve as an ad hoc reviewer for many journals as well as a member of the Pelotonia Institute for Immuno-Oncology and the James Cancer Center Clinical Scientific Review Committee. At the OSUCCC – James, we believe that there’s no routine cancer, and it’s exciting to be part of a cancer program that is dedicated to offering patients hope for today and into the future.
Clinical Expertise
More info for- Lung Cancers
- Thoracic Diseases
- Mesothelioma
Where I See Patients
More info forEducation & Training
More info forInternship - Internal Medicine
- North Shore Long Island Jewish
27005 76Th Ave, New Hyde Park, NY
Residency - Internal Medicine
- North Shore Long Island Jewish
27005 76Th Ave, New Hyde Park, NY
Medical School
- Peking Union Medical College
9 DongDan San Tiao, Beijing
Internship - Internal Medicine
- Peking Union Medical College Hospital
Dongdan, Dongcheng
Fellowship - Medical Oncology
- The Johns Hopkins Hospital
1800 Orleans St, Baltimore, MD
Graduate
- University of Alabama at Birmingham
1720 2Nd Ave S, Birmingham, AL
- North Shore Long Island Jewish
Academic Office & Contact Information
More info forAcademic Office:
Biomedical Research Tower 0494
460 W 12th Ave
Columbus, Ohio 43210-2210Email:
he.1292@osu.eduReviews
More info forPatient Satisfaction Review
The overall patient satisfaction rating is an average of all patient responses to the five questions gathered from the Outpatient Oncology survey, developed by Press Ganey Associates for use in oncology clinics across the country. On behalf of The James, Press Ganey administers the survey to patients who see our providers in an outpatient clinic office. For additional information about the patient satisfaction survey, please visit our
Patient Satisfaction Survey page The comments are submitted by patients and reflect their view and opinions. The comments are not endorsed by and do not necessarily reflect the views of The James.
Publications
More info forDecember 1, 2024Modeling respiratory tract diseases for clinical translation employing conditionally reprogrammed cells.
Daneshdoust D, He K, Wang QE, Li J, Liu X
Cell Insight
August 29, 2024Sustained Clinical Benefit and Intracranial Activity of Tarlatamab in Previously Treated Small Cell Lung Cancer: DeLLphi-300 Trial Update.
Dowlati A, Hummel HD, Champiat S, Olmedo ME, Boyer M, He K, Steeghs N, Izumi H, Johnson ML, Yoshida T, Bouchaab H, Borghaei H, Felip E, Jost PJ, Gadgeel S, Chen X, Yu Y, Martinez P, Parkes A, Paz-Ares L
J Clin Oncol
August 20, 2024Mature MUC5AC Expression in Resected Pancreatic Ductal Adenocarcinoma Predicts Treatment Response and Outcomes.
Manne A, Esnakula A, Sheel A, Sara A, Manne U, Paluri RK, He K, Yang W, Sohal D, Kasi A, Noonan AM, Mittra A, Hays J, Roychowdhury S, Malalur P, Rahman S, Jin N, Cloyd JM, Tsai S, Ejaz A, Pitter K, Miller E, Thanikachalam K, Dillhoff M, Yu L
Int J Mol Sci
July 8, 2024IL-27 Gene Therapy Ameliorates IPEX Syndrome Caused by Germline Mutation of Foxp3 Gene: A Major Role for Induction of IL-10.
Liu JQ, Jabbari A, Lin CH, Akkanapally V, Frankel WL, Basu S, He K, Zheng P, Liu Y, Bai XF
Journal of Immunology
May 10, 2024DLL3-guided therapies in small-cell lung cancer: from antibody-drug conjugate to precision immunotherapy and radioimmunotherapy.
Su PL, Chakravarthy K, Furuya N, Brownstein J, Yu J, Long M, Carbone D, Li Z, He K
Mol Cancer
April 5, 2024CLO24-061: Overall Survival (OS) Impact for NSCLC Patients With irAE and Non-irAE Hospital Admissions During First-Line Pembrolizumab Treatment.
Khorasanchi A, Zhao S, Wei L, Li M, Ho K, Abu-Sbeih H, Goodyear E, Secor A, Shields P, He K, Kaufman J, Memmott R, Alahmadi A, Carbone D, Otterson G, Meara A, Presley C, Owen D
J Natl Compr Canc Netw
April 2, 2024Lifileucel, an Autologous Tumor-infiltrating Lymphocyte Monotherapy, in Patients with Advanced Non-small Cell Lung Cancer Resistant to Immune Checkpoint Inhibitors.
Schoenfeld AJ, Lee SM, Doger de Speville B, Gettinger SN, Hafliger S, Sukari A, Papa S, Rodriguez-Moreno JF, Graf Finckenstein F, Fiaz R, Catlett M, Chen G, Qi R, Masteller EL, Gontcharova V, He K
Cancer Discov
March 22, 2024Decoding the glycoproteome: a new frontier for biomarker discovery in cancer.
He K, Baniasad M, Kwon H, Caval T, Xu G, Lebrilla C, Hommes DW, Bertozzi C
J Hematol Oncol
February 20, 2024A Phase II Trial of Primary Tumor SBRT Boost Prior to Concurrent Chemoradiation for Locally-Advanced Non-Small Cell Lung Cancer.
Williams TM, Miller E, Welliver M, Brownstein J, Otterson G, Owen D, Haglund K, Shields P, Bertino E, Presley C, He K, Naduparambil J, Walston S, Pan J, Yang X, Knopp M, Essan JK, McElroy J, Mo X, McElroy S, Carbone D, Bazan J
Int J Radiat Oncol Biol Phys
November 1, 2023Association Between Pretreatment Chest Imaging and Immune Checkpoint Inhibitor Pneumonitis Among Patients With Lung Cancer.
Wong A, Riley M, Zhao S, Zimmer J, Viveiros M, Wang JG, Esguerra V, Li M, Lopez G, Kendra K, Carbone DP, He K, Alahmadi A, Kaufman J, Memmott RM, Shields PG, Brownstein J, Haglund K, Welliver M, Otterson GA, Presley CJ, Wei L, Owen DH, Ho K
J Natl Compr Canc Netw
October 11, 2023SAPPHIRE: Phase III Study of Sitravatinib Plus Nivolumab Versus Docetaxel in Advanced Non-Squamous Non-Small Cell Lung Cancer.
Borghaei H, de Marinis F, Dumoulin D, Reynolds C, Theelen WSME, Percent I, Calderon VG, Johnson ML, Madroszyk-Flandin A, Garon EB, He K, Planchard D, Reck M, Popat S, Herbst RS, Leal TA, Shazer RL, Yan X, Harrigan R, Peters S
Ann Oncol
February 24, 2023Patients' voice and passion lead to successful clinical trial, KISEKI study; Comments on "A phase II study (WJOG12819L) to assess the efficacy of osimertinib in patients with EGFR mutation-positive NSCLC in whom systemic disease (T790M-negative) progressed after treatment with first- or second-generation EGFR TKIs and platinum-based chemotherapy".
Furuya N, He K, Carbone DP
Lung Cancer
September 1, 2022Selective targeting of GARP-LTGFβ axis in the tumor microenvironment augments PD-1 blockade via enhancing CD8+ T cell antitumor immunity.
Li A, Chang Y, Song NJ, Wu X, Chung D, Riesenberg BP, Velegraki M, Giuliani GD, Das K, Okimoto T, Kwon H, Chakravarthy KB, Bolyard C, Wang Y, He K, Gatti-Mays M, Das J, Yang Y, Gewirth DT, Ma Q, Carbone D, Li Z
J Immunother Cancer
February 22, 2022TSAFinder: Exhaustive Tumor Specific Antigen Detection with RNAseq.
Sharpnack MF, Johnson TS, Chalkley R, Han Z, Carbone D, Huang K, He K
Bioinformatics
January 8, 2022Serum Albumin: Early Prognostic Marker of Benefit for Immune Checkpoint Inhibitor Monotherapy But Not Chemoimmunotherapy.
Guo Y, Wei L, Patel SH, Lopez G, Grogan M, Li M, Haddad T, Johns A, Ganesan LP, Yang Y, Spakowicz DJ, Shields PG, He K, Bertino EM, Otterson GA, Carbone DP, Presley C, Kulp SK, Mace TA, Coss CC, Phelps MA, Owen DH
Clin Lung Cancer
January 1, 2022ERK inactivation enhances stemness of NSCLC cells via promoting Slug-mediated epithelial-to-mesenchymal transition.
Cai S, Li N, Bai X, Liu L, Banerjee A, Lavudi K, Zhang X, Zhao J, Venere M, Duan W, Zhang J, Welliver MX, He K, Wang QE
Theranostics
November 1, 2021A Phase II Trial of Primary Tumor SBRT Boost Prior to Concurrent Chemoradiation for Locally-Advanced Non-Small Cell Lung Cancer (LA-NSCLC).
Williams TM, Welliver MX, Brownstein JM, Otterson G, Owen D, Pan J, Haglund KE, Shields PG, Bertino EM, Presley C, He K, Miller ED, Yang X, Knopp M, Essan JK, McElroy S, Carbone DP, Bazan JG
Int J Radiat Oncol Biol Phys
April 20, 2021Bone Metastases, Skeletal-Related Events, and Survival in Patients With Metastatic Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors.
Qin A, Zhao S, Miah A, Wei L, Patel S, Johns A, Grogan M, Bertino EM, He K, Shields PG, Kalemkerian GP, Gadgeel SM, Ramnath N, Schneider BJ, Hassan KA, Szerlip N, Chopra Z, Journey S, Waninger J, Spakowicz D, Carbone DP, Presley CJ, Otterson GA, Green MD, Owen DH
J Natl Compr Canc Netw
April 20, 2021Advances in epigenetic therapeutics with focus on solid tumors.
Jin N, George TL, Otterson GA, Verschraegen C, Wen H, Carbone D, Herman J, Bertino EM, He K
Clin Epigenetics
March 1, 2021DNA methylation of PTGER4 in peripheral blood plasma helps to distinguish between lung cancer, benign pulmonary nodules and chronic obstructive pulmonary disease patients.
Schotten LM, Darwiche K, Seweryn M, Yildiz V, Kneuertz PJ, Eberhardt WEE, Eisenmann S, Welter S, Sisson BE, Pietrzak M, Wiesweg M, Ploenes T, Hager T, He K, Freitag L, Aigner C, Taube C, Oezkan F
Eur J Cancer
December 2, 2020Treatment of Non-Small-Cell Lung Cancer Based on Circulating Cell-Free DNA and Impact of Variation Allele Frequency.
Bustamante Alvarez JG, Janse S, Owen DH, Kiourtsis S, Bertino EM, He K, Carbone DP, Otterson GA
Clin Lung Cancer
July 29, 2020Brief report: inhaled corticosteroid use and the risk of checkpoint inhibitor pneumonitis in patients with advanced cancer.
Li M, Spakowicz D, Zhao S, Patel SH, Johns A, Grogan M, Miah A, Husain M, He K, Bertino EM, Shields PG, Wei L, Carbone DP, Otterson GA, Presley CJ, Owen DH
Cancer Immunol Immunother
June 10, 2020A genome-wide pooled shRNA screen identifies PPP2R2A as a predictive biomarker for the response to ATR and CHK1 inhibitors.
Qiu Z, Fa P, Liu T, Prasad CB, Ma S, Hong Z, Chan ER, Wang H, Li Z, He K, Wang QE, Williams TM, Yan C, Sizemore ST, Narla G, Zhang J
Cancer Res
May 21, 2020Clinical and Molecular Correlates of Tumor Mutation Burden in Non-Small Cell Lung Cancer.
Sharpnack MF, Cho JH, Johnson TS, Otterson GA, Shields PG, Huang K, Carbone DP, He K
Lung Cancer
Consulting and Related Relationships
More info forAt The Ohio State University Wexner Medical Center, we support a faculty member’s research and consulting in collaboration with medical device, research and/or drug companies because a faculty member’s expertise can guide important advancements in the practice of medicine and improve patient care. In order to provide effective management of these relationships, the university requires annual disclosures from all faculty members with external interests related to their university responsibilities. As of 09/30/2024, Dr. He has reported relationships with the companies or entities listed below. If you have questions about the relationships listed below, please ask the faculty member. If you have questions about how these relationships are monitored by The Ohio State University Wexner Medical Center, please contact our Compliance Office.
- Pfizer
- OncoC4
Patient Comments
Dr. He was excellent.
Excellent
We loved the Dr and NP very supportive and extremely helpful and explained everything.
Dr does give good explanation